Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Tranzarel
Overview
What is Tranzarel?
TRANZAREL 4% is comprised of a topical anesthetic that is indicated for relief of minor pain.
Lidocaine is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl), and has the following structure:
Each gram contains 40 mg of lidocaine in an aqueous gel base. It also contains the following inactive ingredients: Aloe Barbadensis Leaf Juice, Calendula Officinalis Flower Extract, Camellia Sinensis (Green Tea) Leaf Extract, Carbomer, Chamomilla Recutita (Matricaria) Flower Extract, Diazolidinyl Urea, Disodium EDTA, Glycerin, Menthol, Methylparaben, Propylene Glycol, Propylparaben, Purified Water, SD Alcohol 40-2, Symphytum Officinale (Comfrey) Leaf Extract, Triethanolamine.
What does Tranzarel look like?
What are the available doses of Tranzarel?
Sorry No records found.
What should I talk to my health care provider before I take Tranzarel?
Sorry No records found
How should I use Tranzarel?
TRANZAREL 4% is comprised of a topical anesthetic that is indicated for relief of minor pain.
Apply TRANZAREL to affected area(s) of pain three to four times a day or as directed by a physician. TRANZAREL should only be applied to intact skin. The cap and foil should be removed from the tube prior to use.
To open tube
To close tube:
May be applied under occlusive dressing. Consult with your physician first.
What interacts with Tranzarel?
TRANZAREL is contraindicated in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics. If excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician.
What are the warnings of Tranzarel?
The occurrence of hypersensitivity reactions to allopurinol may be increased in patients with decreased renal function receiving thiazides and allopurinol concurrently. For these reasons, in this clinical setting, such combinations should be administered with caution and patients should be observed closely.
For external use only. Do not use in eyes.
Keep out of reach of children.
Do not use in large quantities, particularly over raw surfaces or blistered areas. If swallowed, get medical help or contact Poison Control Center right away.
What are the precautions of Tranzarel?
General
Lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. Product should be used with caution in patients receiving antiarrhythmic drugs of Class I since the adverse effects are additive and generally synergistic.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies of lidocaine in animals to evaluate the carcinogenic and mutagenic potential of the effect on fertility have not been conducted.
Pregnancy
Reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Since animal reproduction studies are not always predictive of human response, general consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy.
Nursing Mothers
TRANZAREL has not been studied in nursing mothers. Since lidocaine is excreted in human milk and the clinical significance of this observation is unknown, caution should be exercised when lidocaine is administered to a nursing woman.
Pediatric Use
Safety and efficacy in children have not been established.
What are the side effects of Tranzarel?
During or immediately following application of TRANZAREL, there may be transient stinging or burning from open areas of skin, or transient blanching (lightening), or erythema (redness) of the skin.
Allergic Reactions
Allergic and anaphylactoid reactions associated with lidocaine, although rare, can occur. Such reactions are characterized by angioedema, bronchospasm, dermatitis, dyspnea, hypersensitivity, laryngospasm, pruritus, shock, and urticaria. If they occur, they should be managed by conventional means.
Systemic (Dose-Related) Reactions
Systemic adverse reactions of lidocaine are similar in nature to those observed with other amide local anesthetic agents, including CNS excitation and/or depression (light headedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest). Excitatory CNS reactions may be brief or not occur at all, in which case the first manifestation may be drowsiness merging into unconsciousness. Cardiovascular manifestations may include bradycardia, hypotension and cardiovascular collapse leading to arrest.
What should I look out for while using Tranzarel?
TRANZAREL is contraindicated in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics. If excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician.
For external use only. Do not use in eyes.
Keep out of reach of children.
Do not use in large quantities, particularly over raw surfaces or blistered areas. If swallowed, get medical help or contact Poison Control Center right away.
What might happen if I take too much Tranzarel?
Sorry No Records found
How should I store and handle Tranzarel?
TRANZAREL (Lidocaine) 4% Pain Relieving Gel is available as the following:4 fl. oz. (120 mL) laminate tube with a child-resistant cap, NDC 70877-2324-4TRANZAREL (Lidocaine) 4% Pain Relieving Gel is available as the following:4 fl. oz. (120 mL) laminate tube with a child-resistant cap, NDC 70877-2324-4
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Lidocaine is an amide-type local anesthetic agent and is suggested to stabilize the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby producing a localized analgesic effect.
Non-Clinical Toxicology
TRANZAREL is contraindicated in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics. If excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician.For external use only. Do not use in eyes.
Keep out of reach of children.
Do not use in large quantities, particularly over raw surfaces or blistered areas. If swallowed, get medical help or contact Poison Control Center right away.
In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see ).
It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol. The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.
Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase. The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone. Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on allopurinol alone or in combination with uricosuric agents, the possibility should be kept in mind.
The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation. Review of these case reports indicates that the patients were mainly receiving thiazide diuretics for hypertension and that tests to rule out decreased renal function secondary to hypertensive nephropathy were not often performed. In those patients in whom renal insufficiency was documented, however, the recommendation to lower the dose of allopurinol was not followed. Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected.
An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs. The cause of the reported association has not been established.
Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol. However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine, and/or mechlorethamine.
Tolbutamide's conversion to inactive metabolites has been shown to be catalyzed by xanthine oxidase from rat liver. The clinical significance, if any, of these observations is unknown.
Chlorpropamide's plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule. The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
Rare reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol. Monitoring of cyclosporine levels and possible adjustment of cyclosporine dosage should be considered when these drugs are co-administered.
Lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. Product should be used with caution in patients receiving antiarrhythmic drugs of Class I since the adverse effects are additive and generally synergistic.
During or immediately following application of TRANZAREL, there may be transient stinging or burning from open areas of skin, or transient blanching (lightening), or erythema (redness) of the skin.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).